Luspatercept

Luspatercept, sold under the brand name Reblozyl, is a medication used for the treatment of anemia in beta thalassemia and myelodysplastic syndromes.[2] The U.S. Food and Drug Administration (FDA) awarded orphan drug status in 2013, and fast track designation in 2015, for both indications.[4] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[5] Contents 1 Clinical development 2 Structure and mechanism ... [wikipedia]